Altimmune announces third quarter 2021 financial results and provides a corporate update

Exploratory mri-pdff analysis of subjects with hepatic steatosis in recently completed phase 1 study of pemvidutide shows reduction of liver fat to undetectable levels after 6 weeks of treatment
ALT Ratings Summary
ALT Quant Ranking